查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
北美傳染病即時護理分子檢測市場規模及預測（2021-2031）、區域佔有率、趨勢和成長機會分析報告
市場調查報告書
商品編碼
1498571

北美傳染病即時護理分子檢測市場規模及預測（2021-2031）、區域佔有率、趨勢和成長機會分析報告

North America Point-of-Care Molecular Testing for Infectious Diseases Market Size and Forecast (2021-2031), Regional Share, Trend, and Growth Opportunity Analysis Report
出版日期: | 出版商: The Insight Partners | 英文 162 Pages | 訂單完成後即時交付

價格

全球北美傳染病即時分子檢測市場預計將從 2023 年的 10.9 億美元增至 2031 年的 26.3 億美元。

本報告中提出的北美傳染病即時分子檢測市場預測可以幫助該市場的利害關係人規劃其成長策略。傳染病發病率的激增和對快速診斷解決方案的偏好是推動市場發展的關鍵因素。然而，報銷不足阻礙了北美傳染病即時分子檢測市場的成長。

北美傳染病即時護理分子檢測市場的市場機會

研究與開發（R&D）是製藥和生物製藥公司的重要組成部分。研發使市場參與者能夠開發具有巨大醫療和商業潛力的各種治療應用的新產品。下表顯示了基於合約、補助金和 NIH 採用的其他資助機制的各種研究和疾病類別的年度資助。

  • 表 1. 傳染病與資金

研究/疾病領域 2019 年（百萬美元） 2020 年（百萬美元） 2021 年（百萬美元） 2022 年（百萬美元）

新興傳染病 2,950 4,867 5,069 4,318

傳染病 6,313 8,301 8,599 8,019

性傳染感染 354 394 404 419

注意：貨幣的當前兌換率已被考慮。

資料來源：年度報告與 Insight Partners 分析

為了應對實驗室能力和分子檢測試劑的短缺，加上傳染病病例的不斷增加，診斷檢測製造商提供了快速且易於使用的設備來促進實驗室外檢測。以下是北美傳染病即時檢測市場製造商採取的一些關鍵融資措施的清單。

8 月，美國衛生與公眾服務部 (HHS) 授予 Cue Health 一份價值約 2800 萬美元的新契約，隸屬於美國戰略準備和響應管理局下屬的生物醫學高級研究與開發局 (BARDA)。該合約旨在開發一種分子多重測試，可用於 COVID-19、呼吸道合胞病毒 (RSV) 和甲型/乙型流感的即時護理 (POC) 和非處方 (OTC) 目的診斷。 Cue 的測試將在近 25 分鐘內為連接的智慧型裝置提供結果，同時檢測和區分 COVID-19、呼吸道合胞病毒 (RSV)、甲型流感和乙型流感。

2023 年 1 月，非營利性行為科學計劃組織 19 to Zero 透過教育補助金獲得了 BD 的資助，用於初級保健環境中的即時測試試點。在獲得財務獎勵的同時，還提供了多個 BD Veritor Plus 系統分析儀和 BD Veritor 快速檢測系統，以促進甲型和乙型流感、RSV、SARS-CoV-2、A 組鏈球菌、和三重。

2022 年 3 月，全球抗愛滋病、瘧疾和結核病基金對加拿大向全球基金的 COVID-19 應對機制 (C19RM) 捐款 6,000 萬加元（4,399 萬美元）的決定表示讚賞。這筆資金用於支持向低收入和中等收入國家提供救生診斷測試、治療和個人防護裝備 (PPE) 的努力。

2021年9月，拜登-哈里斯政府投資21億美元，加強美國公共衛生和醫療保健部門的感染控制和預防活動。拜登-哈里斯政府透過疾病預防控制中心運作，投資於美國救援計劃，以解決美國各州、地方和地區衛生部門以及其他合作組織有關美國傳染病的問題。

因此，對傳染病診斷研發和資金的日益關注預計將為未來幾年北美傳染病市場即時檢測的成長創造有利可圖的機會。

阻礙北美傳染病市場即時檢測的因素

如果存在資料不能表明新測試的成本效益或證明現有測試昂貴，報銷的可能性仍然很低。因此，大多數診斷測試的報銷率較低，阻礙了製造公司投入大量資源來開發新測試。報銷新的或昂貴的診斷測試的困難和擔憂對診斷技術的廣泛部署構成了重大挑戰。在美國，報銷包括第三方付款人對醫療服務或條件進行編碼以確定付款水準的承保範圍。對於使用當前程序術語 (CPT) 代碼的門診測試，醫療保險覆蓋諮詢委員會在診斷測試覆蓋方面促進醫療保險和醫療補助服務中心 (CMS)，包括確定足夠的證據和健康福利。然而，大多數醫療保險報銷決定都是在當地而不是在全國範圍內做出的。診斷測試的覆蓋範圍因地區而異。此外，缺乏確定覆蓋範圍的標準可能會挑戰新診斷產品的開發和可用性。

在某些情況下，報銷不包括測試費用，這限制了實驗室提供測試並降低了測試的可用性和使用。在其他情況下，檢測費用可能很高，但可能會給患者留下相當大的成本，這限制了醫生定期進行檢測。

依疾病類型，北美傳染病即時分子檢測市場分為HIV檢測、流感檢測、性傳染病檢測、C型肝炎病毒檢測、熱帶疾病檢測、呼吸道感染檢測、院內感染、鏈球菌等。根據分子診斷，市場進一步分為聚合酶連鎖反應（PCR）、等溫核酸擴增技術（INAAT）等。 2023 年，呼吸道感染檢測領域佔據最大的市場。

依技術分類，市場分為側流分析、試紙、微流體、分子診斷、免疫分析、固相等。 2023 年，側流分析領域佔據最大的市場佔有率。

從樣本來看，市場分為血液樣本、尿液樣本、鼻口咽拭子等。 2023 年，血液樣本細分市場佔據最大市場佔有率。

就最終用戶而言，市場分為醫院和診所、家庭護理機構、門診和緊急護理設施、療養院和輔助生活設施、研究實驗室和診斷中心。市場根據醫院和診所進一步分為臨床實驗室、專業醫師辦公室等。 2023 年，醫院和診所領域佔據最大的市場。

北美傳染病床邊分子檢測市場：區域概覽

傳染病的日益普及、老年人口的增加以及主要參與者推出的產品數量激增是美國傳染病即時檢測市場成長的主要因素。老化是傳染病的重要危險因素，因為 60 歲以上的人免疫力可能會下降。根據人口資料局2020年發布的研究，2020年美國65歲以上人口為5500萬，預計到2060年將達到9,500萬。例如，2021 年 3 月，美國食品藥物管理局 (FDA) 授權 Binx Health IO CT/NG Assay 用於社區診所、緊急護理機構和門診醫療機構；它是第一個用於診斷衣原體和淋病感染的 POC 檢測產品。

在準備北美傳染病即時分子檢測市場報告時提到的一些主要一手和二手來源包括世界銀行數據、國家衛生服務體系 (NHS)、美國衛生與公眾服務部(HHS) 和 WHO（世界衛生組織）。

目錄

第 1 章：簡介

第 2 章：執行摘要

  • 重要見解

第 3 章：研究方法

  • 二次研究
  • 初步研究
  • 假設的提出
    • 宏觀經濟因素分析：
    • 顯影基數：
    • 數據三角測量：
    • 國家級資料：

第 4 章：北美傳染病即時護理分子檢測市場格局

  • 概述
  • PEST分析

第 5 章：北美傳染病即時護理分子檢測市場 - 主要市場動態

  • 北美傳染病即時護理分子檢測市場 - 主要市場動態
  • 市場促進因素
    • 傳染病發生率激增
    • 對快速診斷解決方案的偏好
  • 市場限制
    • 報銷不足的情況
  • 市場機會
    • 日益關注傳染病診斷的研發與資金
  • 未來的趨勢
    • 產品批准和發布數量不斷增加
  • 促進因素和限制的影響：

第 6 章：北美傳染病即時護理分子檢測市場分析

  • 北美傳染病床邊分子檢測市場收入，2021-2031年
  • 北美傳染病即時護理分子檢測市場預測與分析
  • 按公司分類的市佔率分析 (2023)
  • 定價分析
  • COVID-19 前後的影響
  • 產品/公司的智慧財產權
    • POC專利申請
  • 新公司進入傳染病應用照護端測試市場

第 7 章：北美傳染病即時護理分子檢測市場分析 - 按疾病

  • 愛滋病毒檢測
  • 流感檢測
  • 性傳染病檢測
  • 丙型肝炎病毒檢測
  • 熱帶疾病檢測
  • 呼吸道感染檢測
  • 院內感染
  • 鏈球菌屬
  • 其他

第 8 章：北美傳染病即時護理分子檢測市場分析 - 按技術

  • 側流層析
  • 量油尺
  • 微流控
  • 分子診斷
  • 免疫測定
  • 固相
  • 其他

第 9 章：北美傳染病即時護理分子檢測市場分析 - 透過處方檢測

  • 基於處方的測試
  • 場外測試

第 10 章：北美傳染病即時護理分子檢測市場分析 - 依樣本

  • 血液樣本
  • 尿液樣本
  • 鼻和口咽拭子樣本
  • 其他

第 11 章：北美傳染病即時護理分子檢測市場分析 - 按下最終用戶

  • 醫院和診所
  • 家庭護理設置
  • 門診和緊急護理設施
  • 療養院及輔助生活設施
  • 研究實驗室
  • 診斷中心

第 12 章：北美傳染病即時護理分子檢測市場分析 - 按配銷通路

  • 電子商務平台
  • 零售通路和藥房
  • 其他

第 13 章：北美傳染病即時護理分子檢測市場 - 國家分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥

第 14 章：北美傳染病即時護理分子檢測市場 - 產業格局

  • 概述
  • 北美傳染病床邊分子檢測市場的成長策略
  • 有機成長策略
    • 概述
  • 無機成長策略
    • 概述

第 15 章：公司簡介

  • Abbott Laboratories
  • Agilent Technologies Inc
  • Becton Dickinson and Co
  • Bio-Rad Laboratories Inc
  • Cardinal Health Inc
  • Danaher Corp
  • Cue Health Inc
  • QuidelOrtho Corp
  • Thermo Fisher Scientific Inc
  • F. Hoffmann-La Roche Ltd

第 16 章：附錄

Product Code: TIPRE00039163

The global North America point-of-care molecular testing for infectious diseases market is expected to reach US$ 2.63 billion in 2031 from US$ 1.09 billion in 2023. The market is estimated to grow with a CAGR of 11.1% from 2023 to 2031.

The North America point-of-care molecular testing for infectious diseases market forecast presented in this report can help stakeholders in this marketplace plan their growth strategies. The surging prevalence of infectious diseases and preference for rapid diagnostic solutions are the key factors propelling the market development. However, inadequate reimbursement scenarios impede the North America point-of-care molecular testing for infectious diseases market growth.

Market Opportunities of North America Point-Of-Care Molecular Testing For Infectious Diseases Market

Research and development (R&D) is an essential component of pharmaceutical and biopharmaceutical companies. R&D enables market players to develop new products for various therapeutic applications with significant medical and commercial potential. The following table displays the annual funding for various research and disease categories based on contracts, grants, and other funding mechanisms adopted by the NIH.

  • Table 1. Infectious Diseases and Fundings

Research/Disease Areas 2019 (US$ Million) 2020 (US$ Million) 2021 (US$ Million) 2022 (US$ Million)

Emerging Infectious Diseases 2,950 4,867 5,069 4,318

Infectious Diseases 6,313 8,301 8,599 8,019

Sexually Transmitted Infections 354 394 404 419

Note: The current conversion rate is considered for the currencies.

Source: Annual Reports and The Insight Partners Analysis

In response to the shortage of laboratory capabilities and molecular testing reagents, coupled with the rising cases of infectious diseases, diagnostic testing manufacturers offer fast and easy-to-use devices to facilitate out-of-laboratory testing. Following is a list of a few key funding initiatives undertaken by manufacturers in the North America point-of-care testing for infectious diseases market.

In August, the US Department of Health and Human Services (HHS) awarded Cue Health a new contract worth ~US$ 28 million under the Biomedical Advanced Research and Development Authority (BARDA), a division of the Administration for Strategic Preparedness and Response. The contract was presented to develop a molecular multiplex test that can be used for point-of-care (POC) and over-the-counter (OTC) purposes for COVID-19, respiratory syncytial virus (RSV), and influenza A/B diagnoses. Cue's test would provide results to linked smart devices in nearly 25 minutes, simultaneously detecting and differentiating between COVID-19, respiratory syncytial virus (RSV), influenza A, and influenza B.

In January 2023, 19 to Zero, a non-profit behavioral sciences initiative group, received financing from BD through an educational grant for a point-of-care testing pilot in the primary care environment. A financial award was accompanied by the provision of multiple BD Veritor Plus System Analyzers and BD Veritor System for Rapid Detection Assays to facilitate point-of-care diagnostic testing for influenza A and B, RSV, SARS-CoV-2, Group A Strep, and triplex.

In March 2022, the Global Fund to Fight AIDS, Malaria, and Tuberculosis acclaimed the decision by Canada to contribute CAD 60 million (US$ 43.99 million) to the Global Fund's COVID-19 Response Mechanism (C19RM). The funding was provided to support efforts made to provide life-saving diagnostic tests, treatments, and personal protective equipment (PPE) to low- and middle-income countries.

In September 2021, the Biden-Harris Administration invested US$ 2.1 billion to enhance infection control and prevention activities across the US public health and healthcare sectors. The Biden-Harris administration, operating through the CDC, invested in US rescue programs to address state, local, and territorial health departments and other partner organizations regarding infectious diseases in the US.

Thus, rising focus on R&D and funding in infectious disease diagnostics is expected to create lucrative opportunities for the growth of North American point-of-care testing in the infectious disease market in the coming years.

Factor Hampering North American Point-Of-Care Testing In The Infectious Disease Market

The possibility of reimbursement remains low if there exists data that does not indicate the cost-effectiveness of new tests or prove the existing tests are expensive. Thus, low reimbursement rates for most diagnostic tests discourage manufacturing companies from investing large resources in developing new tests. Difficulties and concerns about reimbursing new or expensive diagnostic tests pose significant challenges to the widespread deployment of diagnostic technologies. In the US, reimbursement comprises coverage by third-party payers coding health services or conditions to determine payment level. For outpatient tests with Current Procedural Terminology (CPT) codes, the Medicare Coverage Advisory Committee promotes the Centers for Medicare & Medicaid Services (CMS) regarding diagnostic test coverage, including determining sufficient evidence and health benefits. However, most Medicare reimbursement decisions are made locally and not nationally. Coverage for diagnostic tests differs as per region. Also, the lack of standards in determining coverage can challenge the development and availability of a new diagnostic product.

In some cases, the reimbursement does not cover test costs, which limits laboratories in offering the test and reduces test availability and use. In other cases, test charges may be high but may leave a considerable cost to the patient, which limits physicians from ordering the test routinely.

Based on disease, the North America point-of-care molecular testing for infectious diseases market is divided into HIV testing, influenza testing, sexually transmitted diseases testing, hepatitis C virus testing, tropical diseases testing, respiratory infection testing, hospital-acquired infections, strep, and others. The market is further divided on the basis of molecular diagnostics into polymerase chain reactions (PCR), isothermal nucleic acid amplification technology (INAAT), and others. The respiratory infection testing segment held the largest market share in 2023.

By technology, the market is segmented into lateral flow assay, dipsticks, microfluidics, molecular diagnostics, immunoassays, solid phase, and others. The lateral flow assay segment held the largest share of the market in 2023.

In terms of sample, the market is segmented into blood samples, urine samples, nasal and oropharyngeal swabs, and others. The blood sample segment held the largest market share in 2023.

In terms of end user, the market is segmented into hospitals and clinics, home care settings, ambulatory and urgent care facilities, nursing homes and assisted living facilities, research laboratories, and diagnostics centers. The market is further divided on the basis of hospitals and clinics into clinical laboratories, professional physician offices, and others. The hospitals and clinics segment held the largest market share in 2023.

North America Point-Of-Care Molecular Testing for Infectious Diseases Market: Regional Overview

The increasing prevalence of infectious diseases, the rising geriatric population, and a surging number of product launches by key players are the primary contributors to the point-of-care testing for infectious diseases market growth in the US. Aging is a prominent risk factor for infectious diseases, as people aged more than 60 may have compromised immunity. According to a study published by the Population Reference Bureau in 2020, the population of individuals aged 65 and above was 55 million in the US in 2020, and the number is expected to reach 95 million by 2060. Regulatory agencies in the US rigorously monitor the development of point-of-care (POC) testing products. For instance, in March 2021, the US Food Drug Administration (FDA) authorized Binx Health IO CT/NG Assay for community-based clinics, urgent care settings, and outpatient healthcare facilities; it is the first POC testing product for diagnosing chlamydial and gonorrheal infections.

A few of the major primary and secondary sources referred to while preparing the report on the North America point-of-care molecular testing for infectious diseases market are the World Bank Data, National Health Service (NHS), US Department of Health and Human Services (HHS), and WHO (World Health Organization).

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Secondary Research
  • 3.2 Primary Research
  • 3.3 Hypothesis formulation
    • 3.3.1 Macro-economic factor analysis:
    • 3.3.2 Developing base number:
    • 3.3.3 Data Triangulation:
    • 3.3.4 Country level data:

4. North America Point-of-Care Molecular Testing for Infectious Diseases Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis

5. North America Point-of-Care Molecular Testing for Infectious Diseases Market - Key Market Dynamics

  • 5.1 North America Point-of-Care Molecular Testing for Infectious Diseases Market - Key Market Dynamics
  • 5.2 Market Drivers
    • 5.2.1 Surging Prevalence of Infectious Diseases
    • 5.2.2 Preference for Rapid Diagnostic Solutions
  • 5.3 Market Restraints
    • 5.3.1 Inadequate Reimbursement Scenario
  • 5.4 Market Opportunities
    • 5.4.1 Increasing Focus on R&D and Funding in Infectious Disease Diagnostics
  • 5.5 Future Trends
    • 5.5.1 Rising Number of Product Approvals and Launches
  • 5.6 Impact of Drivers and Restraints:

6. North America Point-of-Care Molecular Testing for Infectious Diseases Market Analysis

  • 6.1 North America Point-of-Care Molecular Testing for Infectious Diseases Market Revenue (US$ Million), 2021-2031
  • 6.2 North America Point-of-Care Molecular Testing for Infectious Diseases Market Forecast and Analysis
  • 6.3 Market Share Analysis, By Companies (2023)
  • 6.4 Pricing Analysis
  • 6.5 Pre and Post COVID-19 Impact
  • 6.6 Intellectual Property Rights of Products/Companies
    • 6.6.1 POC Patent Filing
  • 6.7 Novel Companies Entering the Point of Care Testing Market For Infectious Diseases Application

7. North America Point-of-Care Molecular Testing for Infectious Diseases Market Analysis - by Diseases

  • 7.1 HIV Testing
    • 7.1.1 Overview
    • 7.1.2 HIV Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.2 Influenza Testing
    • 7.2.1 Overview
    • 7.2.2 Influenza Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.3 Sexually Transmitted Diseases Testing
    • 7.3.1 Overview
    • 7.3.2 Sexually Transmitted Diseases Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
      • 7.3.2.1 North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Sexually Transmitted Diseases Testing
  • 7.4 Hepatitis C Virus Testing
    • 7.4.1 Overview
    • 7.4.2 Hepatitis C Virus Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.5 Tropical Diseases Testing
    • 7.5.1 Overview
    • 7.5.2 Tropical Diseases Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
      • 7.5.2.1 North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Tropical Diseases Testing
  • 7.6 Respiratory Infection Testing
    • 7.6.1 Overview
    • 7.6.2 Respiratory Infection Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.7 Hospital Acquired Infections
    • 7.7.1 Overview
    • 7.7.2 Hospital Acquired Infections: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.8 Strep
    • 7.8.1 Overview
    • 7.8.2 Strep: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.9 Others
    • 7.9.1 Overview
    • 7.9.2 Others: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)

8. North America Point-of-Care Molecular Testing for Infectious Diseases Market Analysis - by Technology

  • 8.1 Lateral Flow Assay
    • 8.1.1 Overview
    • 8.1.2 Lateral Flow Assay: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.2 Dipsticks
    • 8.2.1 Overview
    • 8.2.2 Dipsticks: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.3 Microfluidics
    • 8.3.1 Overview
    • 8.3.2 Microfluidics: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.4 Molecular Diagnostics
    • 8.4.1 Overview
    • 8.4.2 Molecular Diagnostics: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
      • 8.4.2.1 North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Molecular Diagnostics
        • 8.4.2.1.1 North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Polymerase Chain Reactions (PCR)
  • 8.5 Immunoassays
    • 8.5.1 Overview
    • 8.5.2 Immunoassays: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.6 Solid Phase
    • 8.6.1 Overview
    • 8.6.2 Solid Phase: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.7 Others
    • 8.7.1 Overview
    • 8.7.2 Others: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)

9. North America Point-of-Care Molecular Testing for Infectious Diseases Market Analysis - by Prescription Testing

  • 9.1 Prescription Based Testing
    • 9.1.1 Overview
    • 9.1.2 Prescription Based Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.2 OTC Testing
    • 9.2.1 Overview
    • 9.2.2 OTC Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)

10. North America Point-of-Care Molecular Testing for Infectious Diseases Market Analysis - by Sample

  • 10.1 Blood Sample
    • 10.1.1 Overview
    • 10.1.2 Blood Sample: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • 10.2 Urine Sample
    • 10.2.1 Overview
    • 10.2.2 Urine Sample: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • 10.3 Nasal and Oropharyngeal Swabs Sample
    • 10.3.1 Overview
    • 10.3.2 Nasal and Oropharyngeal Swabs Sample: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • 10.4 Others
    • 10.4.1 Overview
    • 10.4.2 Others: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)

11. North America Point-of-Care Molecular Testing for Infectious Diseases Market Analysis - by End User

  • 11.1 Hospitals and Clinics
    • 11.1.1 Overview
    • 11.1.2 Hospitals and Clinics: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
      • 11.1.2.1 North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Hospitals and Clinics
  • 11.2 Home Care Settings
    • 11.2.1 Overview
    • 11.2.2 Home Care Settings: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • 11.3 Ambulatory and Urgent Care Facilities
    • 11.3.1 Overview
    • 11.3.2 Ambulatory and Urgent Care Facilities: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • 11.4 Nursing Home and Assisted Living Facilities
    • 11.4.1 Overview
    • 11.4.2 Nursing Home and Assisted Living Facilities: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • 11.5 Research Laboratories
    • 11.5.1 Overview
    • 11.5.2 Research Laboratories: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • 11.6 Diagnostics Centers
    • 11.6.1 Overview
    • 11.6.2 Diagnostics Centers: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)

12. North America Point-of-Care Molecular Testing for Infectious Diseases Market Analysis - by Distribution Channel

  • 12.1 E-Com Platforms
    • 12.1.1 Overview
    • 12.1.2 E-Com Platforms: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • 12.2 Retail Channel and Pharmacies
    • 12.2.1 Overview
    • 12.2.2 Retail Channel and Pharmacies: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • 12.3 Others
    • 12.3.1 Overview
    • 12.3.2 Others: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)

13. North America Point-of-Care Molecular Testing for Infectious Diseases Market - Country Analysis

  • 13.1 North America
    • 13.1.1 North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Countries
    • 13.1.2 North America Point-of-Care Molecular Testing for Infectious Diseases Market Revenue and Forecast and Analysis - by Country
      • 13.1.2.1 North America Point-of-Care Molecular Testing for Infectious Diseases Market Revenue and Forecast and Analysis - by Country
      • 13.1.2.2 United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
        • 13.1.2.2.1 United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Diseases
        • 13.1.2.2.2 United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Sexually Transmitted Diseases Testing
        • 13.1.2.2.3 United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Tropical Diseases Testing
        • 13.1.2.2.4 United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Technology
        • 13.1.2.2.5 United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Molecular Diagnostics
        • 13.1.2.2.6 United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Polymerase Chain Reactions (PCR)
        • 13.1.2.2.7 United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Prescription Testing
        • 13.1.2.2.8 United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Sample
        • 13.1.2.2.9 United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by End User
        • 13.1.2.2.10 United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Hospitals And Clinics
        • 13.1.2.2.11 United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Distribution Channel
      • 13.1.2.3 Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
        • 13.1.2.3.1 Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Diseases
        • 13.1.2.3.2 Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Sexually Transmitted Diseases Testing
        • 13.1.2.3.3 Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Tropical Diseases Testing
        • 13.1.2.3.4 Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Technology
        • 13.1.2.3.5 Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Molecular Diagnostics
        • 13.1.2.3.6 Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Polymerase Chain Reactions (PCR)
        • 13.1.2.3.7 Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Prescription Testing
        • 13.1.2.3.8 Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Sample
        • 13.1.2.3.9 Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by End User
        • 13.1.2.3.10 Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Hospitals And Clinics
        • 13.1.2.3.11 Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Distribution Channel
      • 13.1.2.4 Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
        • 13.1.2.4.1 Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Diseases
        • 13.1.2.4.2 Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Sexually Transmitted Diseases Testing
        • 13.1.2.4.3 Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Tropical Diseases Testing
        • 13.1.2.4.4 Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Technology
        • 13.1.2.4.5 Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Molecular Diagnostics
        • 13.1.2.4.6 Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Polymerase Chain Reactions (PCR)
        • 13.1.2.4.7 Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Prescription Testing
        • 13.1.2.4.8 Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Sample
        • 13.1.2.4.9 Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by End User
        • 13.1.2.4.10 Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Hospitals And Clinics
        • 13.1.2.4.11 Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Distribution Channel

14. North America Point-Of-Care Molecular Testing for Infectious Diseases Market - Industry Landscape

  • 14.1 Overview
  • 14.2 Growth Strategies in North America Point-Of-Care Molecular Testing for Infectious Diseases Market
  • 14.3 Organic Growth Strategies
    • 14.3.1 Overview
  • 14.4 Inorganic Growth Strategies
    • 14.4.1 Overview

15. Company Profiles

  • 15.1 Abbott Laboratories
    • 15.1.1 Key Facts
    • 15.1.2 Business Description
    • 15.1.3 Products and Services
    • 15.1.4 Financial Overview
    • 15.1.5 SWOT Analysis
    • 15.1.6 Key Developments
  • 15.2 Agilent Technologies Inc
    • 15.2.1 Key Facts
    • 15.2.2 Business Description
    • 15.2.3 Products and Services
    • 15.2.4 Financial Overview
    • 15.2.5 SWOT Analysis
    • 15.2.6 Key Developments
  • 15.3 Becton Dickinson and Co
    • 15.3.1 Key Facts
    • 15.3.2 Business Description
    • 15.3.3 Products and Services
    • 15.3.4 Financial Overview
    • 15.3.5 SWOT Analysis
    • 15.3.6 Key Developments
  • 15.4 Bio-Rad Laboratories Inc
    • 15.4.1 Key Facts
    • 15.4.2 Business Description
    • 15.4.3 Products and Services
    • 15.4.4 Financial Overview
    • 15.4.5 SWOT Analysis
    • 15.4.6 Key Developments
  • 15.5 Cardinal Health Inc
    • 15.5.1 Key Facts
    • 15.5.2 Business Description
    • 15.5.3 Products and Services
    • 15.5.4 Financial Overview
    • 15.5.5 SWOT Analysis
    • 15.5.6 Key Developments
  • 15.6 Danaher Corp
    • 15.6.1 Key Facts
    • 15.6.2 Business Description
    • 15.6.3 Products and Services
    • 15.6.4 Financial Overview
    • 15.6.5 SWOT Analysis
    • 15.6.6 Key Developments
  • 15.7 Cue Health Inc
    • 15.7.1 Key Facts
    • 15.7.2 Business Description
    • 15.7.3 Products and Services
    • 15.7.4 Financial Overview
    • 15.7.5 SWOT Analysis
    • 15.7.6 Key Developments
  • 15.8 QuidelOrtho Corp
    • 15.8.1 Key Facts
    • 15.8.2 Business Description
    • 15.8.3 Products and Services
    • 15.8.4 Financial Overview
    • 15.8.5 SWOT Analysis
    • 15.8.6 Key Developments
  • 15.9 Thermo Fisher Scientific Inc
    • 15.9.1 Key Facts
    • 15.9.2 Business Description
    • 15.9.3 Products and Services
    • 15.9.4 Financial Overview
    • 15.9.5 SWOT Analysis
    • 15.9.6 Key Developments
  • 15.10 F. Hoffmann-La Roche Ltd
    • 15.10.1 Key Facts
    • 15.10.2 Business Description
    • 15.10.3 Products and Services
    • 15.10.4 Financial Overview
    • 15.10.5 SWOT Analysis
    • 15.10.6 Key Developments

16. Appendix

  • 16.1 About The Insight Partners
  • 16.2 Glossary of Terms
    • 1.1.1

List Of Tables

  • Table 1. North America Point-of-Care Molecular Testing for Infectious Diseases Market Segmentation
  • Table 2. Infectious Diseases and Fundings
  • Table 3. North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • Table 4. Market Share Analysis, By Companies (2023)
  • Table 5. Pricing Analysis
  • Table 6. List of Patent filed by Companies
  • Table 7. North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Diseases
  • Table 8. North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Sexually Transmitted Diseases Testing
  • Table 9. North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Tropical Diseases Testing
  • Table 10. North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Technology
  • Table 11. North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Molecular Diagnostics
  • Table 12. North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Polymerase Chain Reactions (PCR)
  • Table 13. North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Prescription Testing
  • Table 14. North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Sample
  • Table 15. North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by End User
  • Table 16. North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Hospitals and Clinics
  • Table 17. North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Distribution Channel
  • Table 18. North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Country
  • Table 19. United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Diseases
  • Table 20. United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Sexually Transmitted Diseases Testing
  • Table 21. United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Tropical Diseases Testing
  • Table 22. United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Technology
  • Table 23. United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Molecular Diagnostics
  • Table 24. United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Polymerase Chain Reactions (PCR)
  • Table 25. United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Prescription Testing
  • Table 26. United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Sample
  • Table 27. United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by End User
  • Table 28. United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Hospitals And Clinics
  • Table 29. United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Distribution Channel
  • Table 30. Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Diseases
  • Table 31. Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Sexually Transmitted Diseases Testing
  • Table 32. Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Tropical Diseases Testing
  • Table 33. Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Technology
  • Table 34. Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Molecular Diagnostics
  • Table 35. Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Polymerase Chain Reactions (PCR)
  • Table 36. Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Prescription Testing
  • Table 37. Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Sample
  • Table 38. Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by End User
  • Table 39. Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Hospitals And Clinics
  • Table 40. Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Distribution Channel
  • Table 41. Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Diseases
  • Table 42. Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Sexually Transmitted Diseases Testing
  • Table 43. Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Tropical Diseases Testing
  • Table 44. Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Technology
  • Table 45. Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Molecular Diagnostics
  • Table 46. Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Polymerase Chain Reactions (PCR)
  • Table 47. Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Prescription Testing
  • Table 48. Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Sample
  • Table 49. Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by End User
  • Table 50. Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Hospitals And Clinics
  • Table 51. Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Distribution Channel
  • Table 52. Recent Organic Growth Strategies in North America Point-Of-Care Molecular Testing for Infectious Diseases Market
  • Table 53. Recent Inorganic Growth Strategies in the North America Point-Of-Care Molecular Testing For Infectious Diseases Market
  • Table 54. Glossary of Terms, Infectious Disease Diagnostics Market
    • 1.1.2

List Of Figures

  • Figure 1. North America Point-of-Care Molecular Testing for Infectious Diseases Market Segmentation, by Country
  • Figure 2. PEST Analysis
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. North America Point-of-Care Molecular Testing for Infectious Diseases Market Revenue (US$ Million), 2021-2031
  • Figure 5. Pre and Post COVID-19 Impact
  • Figure 6. Patents filed by Top Companies for POC
  • Figure 7. Number of Patent Families for POC
  • Figure 8. North America Point-of-Care Molecular Testing for Infectious Diseases Market Share (%) - by Diseases, 2023 and 2031
  • Figure 9. HIV Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 10. Influenza Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 11. Sexually Transmitted Diseases Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 12. Hepatitis C Virus Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 13. Tropical Diseases Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 14. Respiratory Infection Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 15. Hospital Acquired Infections: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 16. Strep: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 17. Others: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 18. North America Point-of-Care Molecular Testing for Infectious Diseases Market Share (%) - by Technology, 2023 and 2031
  • Figure 19. Lateral Flow Assay: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 20. Dipsticks: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 21. Microfluidics: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 22. Molecular Diagnostics: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 23. Immunoassays: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 24. Solid Phase: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 25. Others: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 26. North America Point-of-Care Molecular Testing for Infectious Diseases Market Share (%) - by Prescription Testing, 2023 and 2031
  • Figure 27. Prescription Based Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 28. OTC Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 29. North America Point-of-Care Molecular Testing for Infectious Diseases Market Share (%) - by Sample, 2023 and 2031
  • Figure 30. Blood Sample: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 31. Urine Sample: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 32. Nasal and Oropharyngeal Swabs Sample: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 33. Others: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 34. North America Point-of-Care Molecular Testing for Infectious Diseases Market Share (%) - by End User, 2023 and 2031
  • Figure 35. Hospitals and Clinics: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 36. Home Care Settings: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 37. Ambulatory and Urgent Care Facilities: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 38. Nursing Home and Assisted Living Facilities: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 39. Research Laboratories: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 40. Diagnostics Centers: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 41. North America Point-of-Care Molecular Testing for Infectious Diseases Market Share (%) - by Distribution Channel, 2023 and 2031
  • Figure 42. E-Com Platforms: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 43. Retail Channel and Pharmacies: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 44. Others: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 45. North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Key Countries, 2023 and 2031 (%)
  • Figure 46. United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 47. Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 48. Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 49. Growth Strategies in North America Point-Of-Care Molecular Testing for Infectious Diseases Market